Hunter Groninger
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Hunter Groninger has a total of 157 co-authors. Here are the top co-authors by number of shared publications:
- Anirudh Rao
Department of Medicine, MedStar Washington Hospital Center, Washington, DC; Georgetown University School of Medicine, Washington, DC
9 shared publications Diana Stewart
MedStar Washington Hospital Center/University of Maryland, United States
5 shared publications- Manavotam Singh
MedStar Washington Hospital Center
4 shared publications - Anne Kelemen
Section of Palliative Care, MedStar Washington Hospital Center , Washington, DC
3 shared publications - Kelley M. Anderson
School of Nursing, University of Virginia, 225 Jeanette Lancaster Lane, McLeod Hall, Charlottesville, VA 22903, United States
3 shared publications Mihriye Mete
MedStar Health Research Institute, United States
3 shared publications
Latest Publications
- Open Access
- 23 April 2026
- Published by Springer Nature in Heart Failure Reviews
- Vol. 31 (1) , 62
Palliative care interventions and outcomes in patients with heart failure: an umbrella review
An expanding research base of systematic reviews has evaluated the effect of palliative care (PC) interventions delivered by primary or specialty PC providers for patients with heart failure (HF) and their caregivers. However, the overall evidence base has not been systematically examined. This umbrella review synthesizes the evidence regarding PC interventions among patients with HF to: 1) Describe interventions based on the palliative care domains in the AHA/ACC/HFSA HF guidelines, 2) Examine the effect of interventions on patient-centered and healthcare utilization outcomes, and 3) Provide recommendations for practice, policy and future research. Using the Joanna Briggs Institute methodology for umbrella reviews, we comprehensively searched for systematic reviews in MEDLINE, CINAHL, and Embase databases with no date restrictions. Published, peer-reviewed reviews were included. The search identified 19 reviews (high-quality, 11 with meta-analyses), of 104 unique primary studies after de-duplication (low to moderate quality). Primary and specialty PC was associated with improvements in quality of life, depression, advanced care planning, and reduced hospitalizations. The effect of PC on reducing symptom burden was inconclusive. Limited evidence demonstrated improvements in anxiety, satisfaction with care, caregiver burden, and hospital length of stay. PC did not significantly impact mortality rates or hospice referral. The concordance of the overall evidence was high, and although the quality of primary studies was overall low to moderate, findings confirm that primary and specialty PC offer meaningful benefits for patients with HF. Future research is required on caregiver outcomes, medically complex illness trajectories, intervention timing and fidelity, standardized outcome measurements, and longitudinal study designs with larger sample sizes.
- 23 April 2026
- Published by Springer Nature in Heart Failure Reviews
- Vol. 31 (1) , 62
Open AccessPalliative care interventions and outcomes in patients with heart failure: an umbrella review
An expanding research base of systematic reviews has evaluated the effect of palliative care (PC) interventions delivered by primary or specialty PC providers for patients with heart failure (HF) and their caregivers. However, the overall evidence base has not been systematically examined. This umbrella review synthesizes the evidence regarding PC interventions among patients with HF to: 1) Describe interventions based on the palliative care domains in the AHA/ACC/HFSA HF guidelines, 2) Examine the effect of interventions on patient-centered and healthcare utilization outcomes, and 3) Provide recommendations for practice, policy and future research. Using the Joanna Briggs Institute methodology for umbrella reviews, we comprehensively searched for systematic reviews in MEDLINE, CINAHL, and Embase databases with no date restrictions. Published, peer-reviewed reviews were included. The search identified 19 reviews (high-quality, 11 with meta-analyses), of 104 unique primary studies after de-duplication (low to moderate quality). Primary and specialty PC was associated with improvements in quality of life, depression, advanced care planning, and reduced hospitalizations. The effect of PC on reducing symptom burden was inconclusive. Limited evidence demonstrated improvements in anxiety, satisfaction with care, caregiver burden, and hospital length of stay. PC did not significantly impact mortality rates or hospice referral. The concordance of the overall evidence was high, and although the quality of primary studies was overall low to moderate, findings confirm that primary and specialty PC offer meaningful benefits for patients with HF. Future research is required on caregiver outcomes, medically complex illness trajectories, intervention timing and fidelity, standardized outcome measurements, and longitudinal study designs with larger sample sizes.
- 17 March 2026
- Published by SAGE Publications in American Journal of Hospice and Palliative Medicine®
Associations in Inpatient Palliative Care Consultation Among Oncology Patients at Community and Academic Hospitals: A Retrospective Cohort Study
Background: Palliative care consultation (PCC) improves quality of life for patients with cancer, yet access and delivery vary across hospital settings. Objective: The objective of the study is to examine sociodemographic, clinical, and palliative consult characteristics among oncology inpatients receiving PCCs across community hospitals and academic medical centers. Methods: We conducted a retrospective cohort study of 961 oncology inpatients who received PCC at five hospitals within a single academic health system (2022-2024). Data were extracted from electronic health records and PCC service metrics. Logistic regression compared predictors of PCC delivery between community hospitals and academic medical centers. Results: Among 961 patients, substantial differences by hospital type emerged. Patients receiving PCC at academic centers were more likely to be younger, male, Black or African American, and to have private insurance ( P < .05). Other malignancies were more commonly managed with PCC in academic settings ( P < .05). Academic medical centers more frequently addressed symptom management and patient or family support, whereas community hospitals more often focused on goals of care discussions. Conclusion: These findings demonstrate significant differences in PCC delivery associated with hospital type, despite shared service line structures. Understanding how site-level factors influence PCC delivery may guide targeted strategies to ensure timely and comprehensive palliative care for oncology inpatients across different care environments.
- 17 March 2026
- Published by SAGE Publications in American Journal of Hospice and Palliative Medicine®
Associations in Inpatient Palliative Care Consultation Among Oncology Patients at Community and Academic Hospitals: A Retrospective Cohort Study
Background: Palliative care consultation (PCC) improves quality of life for patients with cancer, yet access and delivery vary across hospital settings. Objective: The objective of the study is to examine sociodemographic, clinical, and palliative consult characteristics among oncology inpatients receiving PCCs across community hospitals and academic medical centers. Methods: We conducted a retrospective cohort study of 961 oncology inpatients who received PCC at five hospitals within a single academic health system (2022-2024). Data were extracted from electronic health records and PCC service metrics. Logistic regression compared predictors of PCC delivery between community hospitals and academic medical centers. Results: Among 961 patients, substantial differences by hospital type emerged. Patients receiving PCC at academic centers were more likely to be younger, male, Black or African American, and to have private insurance ( P < .05). Other malignancies were more commonly managed with PCC in academic settings ( P < .05). Academic medical centers more frequently addressed symptom management and patient or family support, whereas community hospitals more often focused on goals of care discussions. Conclusion: These findings demonstrate significant differences in PCC delivery associated with hospital type, despite shared service line structures. Understanding how site-level factors influence PCC delivery may guide targeted strategies to ensure timely and comprehensive palliative care for oncology inpatients across different care environments.
- Open Access
- 9 January 2026
- Published by Elsevier in Journal of the Academy of Consultation-Liaison Psychiatry
- Vol. 67 (3) , 172-181
Screening and Detection of Delirium in the Acute Palliative Care Setting Using the “Months of the Year Backwards” Test: A Cross-Sectional Study
- 9 January 2026
- Published by Elsevier in Journal of the Academy of Consultation-Liaison Psychiatry
- Vol. 67 (3) , 172-181
Open AccessScreening and Detection of Delirium in the Acute Palliative Care Setting Using the “Months of the Year Backwards” Test: A Cross-Sectional Study
- Open Access
- 15 July 2025
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 14 (14) , e039397
Characteristics and Outcomes of Palliative Continuous Intravenous Inotrope Support Among Medicare Beneficiaries With Heart Failure
Background: Continuous intravenous inotropic support (CIIS) can improve symptoms and functional status for patients with stage D heart failure (HF), but characteristics and outcomes of large cohorts treated with CIIS as a palliative therapy have not been described. Methods and Results: We identified Medicare fee‐for‐service (FFS) beneficiaries with diagnostic codes for HF in 2016 to 2017. After excluding beneficiaries who received advanced HF surgical therapies 2014 to 2018 and prior CIIS, we included remaining beneficiaries who initiated CIIS from 2016 to 2017. Primary outcomes were rates of admission, death, palliative care, and hospice utilization within 1 year of CIIS initiation. We identified 1 463 942 Medicare beneficiaries with HF in 2016 to 2017, of whom 3706 (0.3%) beneficiaries initiated palliative CIIS (58.9% male, 82.1% White, 67.1% from urban areas, average age 78 [SD=6.8] years). Average Charlson Comorbidity Index Score was 5.8 (SD=3.1). Only 6.5% of CIIS users had a diagnostic code suggesting receipt of palliative care services. Within 1 year of CIIS initiation, 72.2% of beneficiaries had at least 1 all‐cause admission, 55.7% had ≥2 admissions, and 38% had died. Almost 18% of CIIS users had a claim for hospice services; of CIIS users who died, 43.3% had a hospice claim. Conclusions: Among Medicare FFS beneficiaries with HF, palliative CIIS is rare and primarily utilized among older beneficiaries with high global comorbidity. Despite the palliative indication, beneficiaries have high rates of admission and low use of palliative care services. Palliative care and associated services should be better integrated into the care of patients with palliative CIIS.
- 15 July 2025
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 14 (14) , e039397
Open AccessCharacteristics and Outcomes of Palliative Continuous Intravenous Inotrope Support Among Medicare Beneficiaries With Heart Failure
Background: Continuous intravenous inotropic support (CIIS) can improve symptoms and functional status for patients with stage D heart failure (HF), but characteristics and outcomes of large cohorts treated with CIIS as a palliative therapy have not been described. Methods and Results: We identified Medicare fee‐for‐service (FFS) beneficiaries with diagnostic codes for HF in 2016 to 2017. After excluding beneficiaries who received advanced HF surgical therapies 2014 to 2018 and prior CIIS, we included remaining beneficiaries who initiated CIIS from 2016 to 2017. Primary outcomes were rates of admission, death, palliative care, and hospice utilization within 1 year of CIIS initiation. We identified 1 463 942 Medicare beneficiaries with HF in 2016 to 2017, of whom 3706 (0.3%) beneficiaries initiated palliative CIIS (58.9% male, 82.1% White, 67.1% from urban areas, average age 78 [SD=6.8] years). Average Charlson Comorbidity Index Score was 5.8 (SD=3.1). Only 6.5% of CIIS users had a diagnostic code suggesting receipt of palliative care services. Within 1 year of CIIS initiation, 72.2% of beneficiaries had at least 1 all‐cause admission, 55.7% had ≥2 admissions, and 38% had died. Almost 18% of CIIS users had a claim for hospice services; of CIIS users who died, 43.3% had a hospice claim. Conclusions: Among Medicare FFS beneficiaries with HF, palliative CIIS is rare and primarily utilized among older beneficiaries with high global comorbidity. Despite the palliative indication, beneficiaries have high rates of admission and low use of palliative care services. Palliative care and associated services should be better integrated into the care of patients with palliative CIIS.
- 14 July 2025
- Published by Springer Nature in Supportive Care in Cancer
- Vol. 33 (8) , 1-9
Virtual reality for outpatient management of cancer pain: a pilot dosing study
Purpose Growing evidence supports the analgesic benefit of virtual reality (VR) for cancer-related pain. However, little is known about the effects of repeated use in the outpatient setting on chronic cancer pain severity or the ideal “dose” of VR interventions to mitigate cancer pain. Methods Single arm unblinded pilot dosing study. Participants were taught how to use and given a Meta Quest 2 VR headset with hand controllers, instructed to use daily × 10 min for 1 week, then twice-daily × 10 min for 1 week, then “as needed” (per participant choice) daily for 1 week. Outcomes were self-reported pain score (SRPS), PROMIS Pain Interference Short Form score, and satisfaction with overall pain management. The study recruited adults living with any solid cancer who reported baseline cancer-related pain ≥ 4/10 from a large urban cancer center in Washington, DC. Results Thirty-three participants (mean age 55 years (SD = 11); 73% women; 91% African American) were included in the analysis. Linear mixed-effects models demonstrated significant time trends across the 3-week study period for improved SRPS (p = 0.04), pain interference scores (p = 0.001), and satisfaction with overall pain management (p < 0.001). Among participants who had been prescribed as needed opioids to manage their cancer pain, no change was observed in self-reported use of breakthrough opioids (p = 0.49). Conclusion In this pilot, daily use of VR-delivered distraction therapy improved chronic cancer pain compared to baseline. Twice-daily VR dosing may have helped more than once-daily dosing. Future, larger studies should seek to verify optimal dosing of nonpharmacological VR intervention for cancer pain. Trial registration NCT05442866 (June 28, 2022).
- 14 July 2025
- Published by Springer Nature in Supportive Care in Cancer
- Vol. 33 (8) , 1-9
Virtual reality for outpatient management of cancer pain: a pilot dosing study
Purpose Growing evidence supports the analgesic benefit of virtual reality (VR) for cancer-related pain. However, little is known about the effects of repeated use in the outpatient setting on chronic cancer pain severity or the ideal “dose” of VR interventions to mitigate cancer pain. Methods Single arm unblinded pilot dosing study. Participants were taught how to use and given a Meta Quest 2 VR headset with hand controllers, instructed to use daily × 10 min for 1 week, then twice-daily × 10 min for 1 week, then “as needed” (per participant choice) daily for 1 week. Outcomes were self-reported pain score (SRPS), PROMIS Pain Interference Short Form score, and satisfaction with overall pain management. The study recruited adults living with any solid cancer who reported baseline cancer-related pain ≥ 4/10 from a large urban cancer center in Washington, DC. Results Thirty-three participants (mean age 55 years (SD = 11); 73% women; 91% African American) were included in the analysis. Linear mixed-effects models demonstrated significant time trends across the 3-week study period for improved SRPS (p = 0.04), pain interference scores (p = 0.001), and satisfaction with overall pain management (p < 0.001). Among participants who had been prescribed as needed opioids to manage their cancer pain, no change was observed in self-reported use of breakthrough opioids (p = 0.49). Conclusion In this pilot, daily use of VR-delivered distraction therapy improved chronic cancer pain compared to baseline. Twice-daily VR dosing may have helped more than once-daily dosing. Future, larger studies should seek to verify optimal dosing of nonpharmacological VR intervention for cancer pain. Trial registration NCT05442866 (June 28, 2022).
- Open Access
Mental Health Professionals’ Views on Artificial Intelligence as an Aide for Children Anticipating or Suffering the Loss of a Parent to Cancer: Helpful or Harmful?
Purpose: Assess mental health professionals’ attitudes regarding the timing and characteristics of therapeutic interventions for children whose parents have incurable cancer, and whether professionals would use artificial intelligence (AI) in these interventions. Methods: Professionals were surveyed about their therapeutic approaches to caring for children when parents have incurable cancer under different scenarios. Data from N = 294 (69% male, 72% white, 26% Latine, 56% rural or underserved communities) physicians, psychologists, social workers, hospital chaplains, community health workers, and others were analyzed. Attitudes surrounding the timing and characteristics of interventions across the parent’s cancer journey were compared, including how professionals believed interventions should attend to dimensions of the child or family, and if, how, and when AI technology could be introduced. Results: Across 10 dimensions of childhood, (1) the child’s premorbid exposure to traumatic events, (2) a surviving parent’s presence, and (3) the child’s age were important factors to consider when making mental health care decisions in this context. The professionals reported being more likely to introduce therapeutic resources as early as possible in the parent’s illness (i.e., upon diagnosis). Regarding the use of AI, 87% foresaw its role in supporting children’s mental health. While 93.2% agreed that a grieving child could be helped by interacting with an AI-generated likeness of the deceased parent, when AI’s use was contextualized in providing support for a child who lost a parent to cancer, only 49% believed AI was appropriate. The participants were conflicted over when AI could be first introduced, either upon a parent’s illness diagnosis (19.4%), during a parent’s treatment (19.0%), or as part of a parent’s hospice care (12.6%). None believed it to be appropriate following the loss of the parent to cancer. Conclusions: AI is increasingly present in children’s daily lives and quickly infiltrating health care with widely accessible mental health chatbots. Concerns about privacy, the accuracy of information, and the anthropomorphism of AI tools by children give professionals pause before introducing such technology. Proceeding with great caution is urged until more is known about the impact of AI on children’s mental health, grief, and psychological well-being in the context of parental cancer.
Open AccessMental Health Professionals’ Views on Artificial Intelligence as an Aide for Children Anticipating or Suffering the Loss of a Parent to Cancer: Helpful or Harmful?
Purpose: Assess mental health professionals’ attitudes regarding the timing and characteristics of therapeutic interventions for children whose parents have incurable cancer, and whether professionals would use artificial intelligence (AI) in these interventions. Methods: Professionals were surveyed about their therapeutic approaches to caring for children when parents have incurable cancer under different scenarios. Data from N = 294 (69% male, 72% white, 26% Latine, 56% rural or underserved communities) physicians, psychologists, social workers, hospital chaplains, community health workers, and others were analyzed. Attitudes surrounding the timing and characteristics of interventions across the parent’s cancer journey were compared, including how professionals believed interventions should attend to dimensions of the child or family, and if, how, and when AI technology could be introduced. Results: Across 10 dimensions of childhood, (1) the child’s premorbid exposure to traumatic events, (2) a surviving parent’s presence, and (3) the child’s age were important factors to consider when making mental health care decisions in this context. The professionals reported being more likely to introduce therapeutic resources as early as possible in the parent’s illness (i.e., upon diagnosis). Regarding the use of AI, 87% foresaw its role in supporting children’s mental health. While 93.2% agreed that a grieving child could be helped by interacting with an AI-generated likeness of the deceased parent, when AI’s use was contextualized in providing support for a child who lost a parent to cancer, only 49% believed AI was appropriate. The participants were conflicted over when AI could be first introduced, either upon a parent’s illness diagnosis (19.4%), during a parent’s treatment (19.0%), or as part of a parent’s hospice care (12.6%). None believed it to be appropriate following the loss of the parent to cancer. Conclusions: AI is increasingly present in children’s daily lives and quickly infiltrating health care with widely accessible mental health chatbots. Concerns about privacy, the accuracy of information, and the anthropomorphism of AI tools by children give professionals pause before introducing such technology. Proceeding with great caution is urged until more is known about the impact of AI on children’s mental health, grief, and psychological well-being in the context of parental cancer.
- Open Access
- 10 March 2025
- Published by JMIR Publications Inc. in JMIR Formative Research
- Vol. 9 (1) , e64869
Development of a Voice-Activated Virtual Assistant to Improve Insomnia Among Young Adult Cancer Survivors: Mixed Methods Feasibility and Acceptability Study
Background: Up to 75% of young adult cancer survivors (YACS) experience chronic insomnia, negatively affecting physical and emotional health and overall quality of life. Cognitive behavioral therapy for insomnia (CBT-I) is a gold-standard intervention to address insomnia. To improve CBT-I access and treatment adherence, screen-based digital CBT-I platforms have been developed. However, even with these digital products, widespread uptake of CBT-I remains limited, and new strategies for CBT-I delivery are warranted. Objective: The objective of this study is to understand how YACS experience insomnia and how they might incorporate technology-delivered CBT-I into a daily routine and test the feasibility and acceptability of a novel screen-free voice-activated virtual assistant–delivered CBT-I prototype. Methods: Eligible participants—ages 18-39, living with a history of cancer (any type, any stage), self-reporting on average less sleep than National Sleep Foundation recommendations, and English-speaking—were recruited from a major urban cancer center, 2 regional oncology clinics, and 2 cancer survivorship support groups. We conducted 4 focus groups to understand the YACS experience of insomnia, their routine use of technology at home, particularly voice-activated virtual assistants such as Amazon Alexa, and input on how CBT-I might be delivered at home through a smart speaker system. We developed a prototype device to deliver key elements of CBT-I at home along with circadian lighting and monitoring of post-bedtime device use, collected YACS user perspectives on this prototype, and then conducted a single-arm feasibility and acceptability study. Results: In total, 26 YACS (6-7 participants per group) experiencing insomnia participated in focus groups to share experiences of insomnia during cancer survivorship and to provide input regarding a CBT-I prototype. Common triggers of insomnia included worry about disease management and progression, disease-related pain and other symptoms, choices regarding personal device use, and worry about the impact of poor sleep on daily functioning. In total, 12 participants completed device prototype testing, engaging with the prototype 94% of the assigned times (twice daily for 14 days; meeting predetermined feasibility cutoff of engagement ≥70% of assigned times) and rating the prototype with an overall mean score of 5.43 on the Satisfaction subscale of the Usability, Satisfaction, and Ease of Use scale (range 4.42-7; exceeding the predetermined cutoff score for acceptability of 5.0). All participants completing the study reported they would be interested in using the prototype again and would recommend it to someone else with insomnia. Conclusions: YACS were highly engaged with our voice-activated virtual assistant–delivered CBT-I prototype and found it acceptable to use. Following final device development, future studies should evaluate the efficacy of this intervention among YACS. Trial Registration: ClinicalTrials.gov NCT05875129; https://clinicaltrials.gov/study/NCT05875129
- 10 March 2025
- Published by JMIR Publications Inc. in JMIR Formative Research
- Vol. 9 (1) , e64869
Open AccessDevelopment of a Voice-Activated Virtual Assistant to Improve Insomnia Among Young Adult Cancer Survivors: Mixed Methods Feasibility and Acceptability Study
Background: Up to 75% of young adult cancer survivors (YACS) experience chronic insomnia, negatively affecting physical and emotional health and overall quality of life. Cognitive behavioral therapy for insomnia (CBT-I) is a gold-standard intervention to address insomnia. To improve CBT-I access and treatment adherence, screen-based digital CBT-I platforms have been developed. However, even with these digital products, widespread uptake of CBT-I remains limited, and new strategies for CBT-I delivery are warranted. Objective: The objective of this study is to understand how YACS experience insomnia and how they might incorporate technology-delivered CBT-I into a daily routine and test the feasibility and acceptability of a novel screen-free voice-activated virtual assistant–delivered CBT-I prototype. Methods: Eligible participants—ages 18-39, living with a history of cancer (any type, any stage), self-reporting on average less sleep than National Sleep Foundation recommendations, and English-speaking—were recruited from a major urban cancer center, 2 regional oncology clinics, and 2 cancer survivorship support groups. We conducted 4 focus groups to understand the YACS experience of insomnia, their routine use of technology at home, particularly voice-activated virtual assistants such as Amazon Alexa, and input on how CBT-I might be delivered at home through a smart speaker system. We developed a prototype device to deliver key elements of CBT-I at home along with circadian lighting and monitoring of post-bedtime device use, collected YACS user perspectives on this prototype, and then conducted a single-arm feasibility and acceptability study. Results: In total, 26 YACS (6-7 participants per group) experiencing insomnia participated in focus groups to share experiences of insomnia during cancer survivorship and to provide input regarding a CBT-I prototype. Common triggers of insomnia included worry about disease management and progression, disease-related pain and other symptoms, choices regarding personal device use, and worry about the impact of poor sleep on daily functioning. In total, 12 participants completed device prototype testing, engaging with the prototype 94% of the assigned times (twice daily for 14 days; meeting predetermined feasibility cutoff of engagement ≥70% of assigned times) and rating the prototype with an overall mean score of 5.43 on the Satisfaction subscale of the Usability, Satisfaction, and Ease of Use scale (range 4.42-7; exceeding the predetermined cutoff score for acceptability of 5.0). All participants completing the study reported they would be interested in using the prototype again and would recommend it to someone else with insomnia. Conclusions: YACS were highly engaged with our voice-activated virtual assistant–delivered CBT-I prototype and found it acceptable to use. Following final device development, future studies should evaluate the efficacy of this intervention among YACS. Trial Registration: ClinicalTrials.gov NCT05875129; https://clinicaltrials.gov/study/NCT05875129
- 4 January 2025
- Published by SAGE Publications in American Journal of Hospice and Palliative Medicine®
- Vol. 42 (11) , 1181-1186
A Qualitative Inquiry of Patients Using Virtual Reality to Mitigate Cancer Pain
Introduction: Virtual reality (VR) is a rapidly evolving technology that has been shown to improve pain severity in different disease states, including cancer. To date, VR pain studies have used off-the-shelf products for pain distraction. What are user preferences for VR content to mitigate cancer pain?. Objective: Through qualitative inquiry, we aim to explore and understand user preferences for VR distraction therapies to mitigate cancer-related pain. Methods: We conducted semi-structured interviews of 12 patients participating in a VR cancer pain therapy clinical trial. Using a grounded theory approach, emerging themes and subthemes were analyzed to elucidate patient experiences and preferences for VR content. Results: Participants described distinct themes related to VR use, specifically experiences of immersion, distraction, relaxation, and safety. Higher experience of immersion and distraction were associated with improvement in cancer pain severity. Some participants had to adapt to VR technology to use it successfully. Regarding future VR content development, participants voiced preferences for content related to home, childhood, natural environments, and family and friends. Conclusion: Patients associate higher levels of virtual immersion and familiar, natural virtual experiences with successful VR distraction therapy for cancer pain analgesia.
- 4 January 2025
- Published by SAGE Publications in American Journal of Hospice and Palliative Medicine®
- Vol. 42 (11) , 1181-1186
A Qualitative Inquiry of Patients Using Virtual Reality to Mitigate Cancer Pain
Introduction: Virtual reality (VR) is a rapidly evolving technology that has been shown to improve pain severity in different disease states, including cancer. To date, VR pain studies have used off-the-shelf products for pain distraction. What are user preferences for VR content to mitigate cancer pain?. Objective: Through qualitative inquiry, we aim to explore and understand user preferences for VR distraction therapies to mitigate cancer-related pain. Methods: We conducted semi-structured interviews of 12 patients participating in a VR cancer pain therapy clinical trial. Using a grounded theory approach, emerging themes and subthemes were analyzed to elucidate patient experiences and preferences for VR content. Results: Participants described distinct themes related to VR use, specifically experiences of immersion, distraction, relaxation, and safety. Higher experience of immersion and distraction were associated with improvement in cancer pain severity. Some participants had to adapt to VR technology to use it successfully. Regarding future VR content development, participants voiced preferences for content related to home, childhood, natural environments, and family and friends. Conclusion: Patients associate higher levels of virtual immersion and familiar, natural virtual experiences with successful VR distraction therapy for cancer pain analgesia.
- 13 August 2024
- Published by Elsevier in Heart & Lung
- Vol. 68, 265-271
Optimizing outcomes: Impact of palliative care consultation timing in the cardiovascular intensive care unit
- 13 August 2024
- Published by Elsevier in Heart & Lung
- Vol. 68, 265-271
Optimizing outcomes: Impact of palliative care consultation timing in the cardiovascular intensive care unit
- Open Access
- 29 July 2024
- Published by JMIR Publications Inc. in JMIR Preprints
Development of a Voice-Activated Virtual Assistant to Improve Insomnia Among Young Adult Cancer Survivors: Mixed Methods Feasibility and Acceptability Study (Preprint)
BACKGROUND Up to 75% of young adult cancer survivors (YACS) experience chronic insomnia, negatively affecting physical and emotional health and overall quality of life. Cognitive behavioral therapy for insomnia (CBT-I) is a gold-standard intervention to address insomnia. To improve CBT-I access and treatment adherence, screen-based digital CBT-I platforms have been developed. However, even with these digital products, widespread uptake of CBT-I remains limited, and new strategies for CBT-I delivery are warranted. OBJECTIVE The objective of this study is to understand how YACS experience insomnia and how they might incorporate technology-delivered CBT-I into a daily routine and test the feasibility and acceptability of a novel screen-free voice-activated virtual assistant–delivered CBT-I prototype. METHODS Eligible participants—ages 18-39, living with a history of cancer (any type, any stage), self-reporting on average less sleep than National Sleep Foundation recommendations, and English-speaking—were recruited from a major urban cancer center, 2 regional oncology clinics, and 2 cancer survivorship support groups. We conducted 4 focus groups to understand the YACS experience of insomnia, their routine use of technology at home, particularly voice-activated virtual assistants such as Amazon Alexa, and input on how CBT-I might be delivered at home through a smart speaker system. We developed a prototype device to deliver key elements of CBT-I at home along with circadian lighting and monitoring of post-bedtime device use, collected YACS user perspectives on this prototype, and then conducted a single-arm feasibility and acceptability study. RESULTS In total, 26 YACS (6-7 participants per group) experiencing insomnia participated in focus groups to share experiences of insomnia during cancer survivorship and to provide input regarding a CBT-I prototype. Common triggers of insomnia included worry about disease management and progression, disease-related pain and other symptoms, choices regarding personal device use, and worry about the impact of poor sleep on daily functioning. In total, 12 participants completed device prototype testing, engaging with the prototype 94% of the assigned times (twice daily for 14 days; meeting predetermined feasibility cutoff of engagement ≥70% of assigned times) and rating the prototype with an overall mean score of 5.43 on the Satisfaction subscale of the Usability, Satisfaction, and Ease of Use scale (range 4.42-7; exceeding the predetermined cutoff score for acceptability of 5.0). All participants completing the study reported they would be interested in using the prototype again and would recommend it to someone else with insomnia. CONCLUSIONS YACS were highly engaged with our voice-activated virtual assistant–delivered CBT-I prototype and found it acceptable to use. Following final device development, future studies should evaluate the efficacy of this intervention among YACS. CLINICALTRIAL ClinicalTrials.gov NCT05875129; https://clinicaltrials.gov/study/NCT05875129
- 29 July 2024
- Published by JMIR Publications Inc. in JMIR Preprints
Open AccessDevelopment of a Voice-Activated Virtual Assistant to Improve Insomnia Among Young Adult Cancer Survivors: Mixed Methods Feasibility and Acceptability Study (Preprint)
BACKGROUND Up to 75% of young adult cancer survivors (YACS) experience chronic insomnia, negatively affecting physical and emotional health and overall quality of life. Cognitive behavioral therapy for insomnia (CBT-I) is a gold-standard intervention to address insomnia. To improve CBT-I access and treatment adherence, screen-based digital CBT-I platforms have been developed. However, even with these digital products, widespread uptake of CBT-I remains limited, and new strategies for CBT-I delivery are warranted. OBJECTIVE The objective of this study is to understand how YACS experience insomnia and how they might incorporate technology-delivered CBT-I into a daily routine and test the feasibility and acceptability of a novel screen-free voice-activated virtual assistant–delivered CBT-I prototype. METHODS Eligible participants—ages 18-39, living with a history of cancer (any type, any stage), self-reporting on average less sleep than National Sleep Foundation recommendations, and English-speaking—were recruited from a major urban cancer center, 2 regional oncology clinics, and 2 cancer survivorship support groups. We conducted 4 focus groups to understand the YACS experience of insomnia, their routine use of technology at home, particularly voice-activated virtual assistants such as Amazon Alexa, and input on how CBT-I might be delivered at home through a smart speaker system. We developed a prototype device to deliver key elements of CBT-I at home along with circadian lighting and monitoring of post-bedtime device use, collected YACS user perspectives on this prototype, and then conducted a single-arm feasibility and acceptability study. RESULTS In total, 26 YACS (6-7 participants per group) experiencing insomnia participated in focus groups to share experiences of insomnia during cancer survivorship and to provide input regarding a CBT-I prototype. Common triggers of insomnia included worry about disease management and progression, disease-related pain and other symptoms, choices regarding personal device use, and worry about the impact of poor sleep on daily functioning. In total, 12 participants completed device prototype testing, engaging with the prototype 94% of the assigned times (twice daily for 14 days; meeting predetermined feasibility cutoff of engagement ≥70% of assigned times) and rating the prototype with an overall mean score of 5.43 on the Satisfaction subscale of the Usability, Satisfaction, and Ease of Use scale (range 4.42-7; exceeding the predetermined cutoff score for acceptability of 5.0). All participants completing the study reported they would be interested in using the prototype again and would recommend it to someone else with insomnia. CONCLUSIONS YACS were highly engaged with our voice-activated virtual assistant–delivered CBT-I prototype and found it acceptable to use. Following final device development, future studies should evaluate the efficacy of this intervention among YACS. CLINICALTRIAL ClinicalTrials.gov NCT05875129; https://clinicaltrials.gov/study/NCT05875129